Study on the endocytosis and the internalization mechanism of aminosilane-coated Fe3O4 nanoparticles in vitro.
In this study, the endocytosis and the internalization mechanism of aminosilane-coated Fe(3)O(4) nanoparticles into human lung cancer cell line SPC-A1 was studied compared with human lung cell line WI-38 in vitro. The particle endocytosis behavior was studied by using Transmission Electron Microscope (TEM) and Coupled Plasma-Atomic Emission Spectrometry (ICP-AES). It was found that aminosilane-coated Fe(3)O(4) nanoparticles could be greatly taken up by SPC-A1 human cancer cells (202 pg iron/cell) but not by WI-38 human lung cells (13 pg iron/cell). The particles could be retained in SPC-A1 cells over a number of generations in vitro. Different endocytosis was observed by TEM after SPC-A1 cells were treated with different temperature or with/without Cytochalasin B (Inhibitor of phagocytosis) at 37 degrees C. No nanoparticles were taken up by SPC-A1 after the endocytosis inhibited in low temperature. Restoring the endocytosis activity at 37 degrees C, the process of nanoparticles from coated pit to endosomes and lysosomes was observed by TEM. Endocytosis activity was effectively inhibited by the presence of Cytochalasin B at 37 degrees C, while a lot of nanoparticles were uptaken to the cytoplasm of SPC-A1 cells in the control group. Our results suggest that the process of endocytosis of aminosilane-coated Fe(3)O(4) nanoparticles can efficiently takes place in lung cancer cells and nanoparticles can be kept in cancer cells for generations. Phagocytosis may be involved in the internalization process of aminosilane-coated Fe(3)O(4) nanoparticles.
Ma
Yong-Jie
YJ
National Key Laboratory of Nano/Micro Fabrication Technology, Key Laboratory for Thin Film and Microfabrication of Ministry of Education, Shanghai Jiaotong University, Room 302, Zhongyuan, 1954 Huashan Road, Shanghai 200030, China.
Gu
Hong-Chen
HC
D045744:Cell Line, Tumor; D020099:Coated Materials, Biocompatible / Q000493:pharmacokinetics*; D003571:Cytochalasin B / Q000494:pharmacology; D004705:Endocytosis / Q000187:drug effects; D005290:Ferric Compounds / Q000737:chemistry* / Q000493:pharmacokinetics*; D006801:Humans; D007501:Iron / Q000493:pharmacokinetics; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D008280:Magnetics / Q000627:therapeutic use; D053768:Metal Nanoparticles / Q000737:chemistry / Q000627:therapeutic use; D012821:Silanes / Q000737:chemistry* / Q000493:pharmacokinetics*; D013696:Temperature; D013997:Time Factors
D020099:Coated Materials, Biocompatible; D005290:Ferric Compounds; D012821:Silanes; C000499:ferric oxide; D003571:Cytochalasin B; D007501:Iron